VIDEO: Duravyu for wet AMD shows positive 12-month outcomes vs. aflibercept

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, shares phase 2 data investigating Duravyu for wet age-related macular degeneration treatment vs. aflibercept.

According to Ribeiro, Duravyu (vorolanib intravitreal insert) demonstrated comparable vision outcomes to aflibercept, as well as stabilization of central subfield thickness.

Additionally, 50% of patients treated with Duravyu did not require any supplemental anti-VEGF injections at 12 months, he said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures:
Ribeiro reports being the chief medical officer for EyePoint Pharmaceuticals.

Read more about

This post was originally published on this site